500 related articles for article (PubMed ID: 16557597)
1. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
Parr C; Jiang WG
Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
[TBL] [Abstract][Full Text] [Related]
2. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells.
Parr C; Jiang WG
Int J Oncol; 2001 Oct; 19(4):857-63. PubMed ID: 11562767
[TBL] [Abstract][Full Text] [Related]
3. The hepatocyte growth factor regulatory factors in human breast cancer.
Parr C; Watkins G; Mansel RE; Jiang WG
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):202-11. PubMed ID: 14734471
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte growth factor activation inhibitors - therapeutic potential in cancer.
Parr C; Sanders AJ; Jiang WG
Anticancer Agents Med Chem; 2010 Jan; 10(1):47-57. PubMed ID: 20015004
[TBL] [Abstract][Full Text] [Related]
5. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Kirchhofer D; Peek M; Lipari MT; Billeci K; Fan B; Moran P
FEBS Lett; 2005 Mar; 579(9):1945-50. PubMed ID: 15792801
[TBL] [Abstract][Full Text] [Related]
6. Mouse hepatocyte growth factor (HGF) activator inhibitor type 2 lacking the first Kunitz domain potently inhibits the HGF activator.
Kataoka H; Itoh H; Nuki Y; Hamasuna R; Naganuma S; Kitamura N; Shimomura T
Biochem Biophys Res Commun; 2002 Jan; 290(3):1096-100. PubMed ID: 11798188
[TBL] [Abstract][Full Text] [Related]
7. Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1.
Kirchhofer D; Peek M; Li W; Stamos J; Eigenbrot C; Kadkhodayan S; Elliott JM; Corpuz RT; Lazarus RA; Moran P
J Biol Chem; 2003 Sep; 278(38):36341-9. PubMed ID: 12815039
[TBL] [Abstract][Full Text] [Related]
8. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
[TBL] [Abstract][Full Text] [Related]
9. Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis.
Marchand-Adam S; Fabre A; Mailleux AA; Marchal J; Quesnel C; Kataoka H; Aubier M; Dehoux M; Soler P; Crestani B
Am J Respir Crit Care Med; 2006 Jul; 174(1):58-66. PubMed ID: 16574935
[TBL] [Abstract][Full Text] [Related]
10. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo.
Oberst M; Anders J; Xie B; Singh B; Ossandon M; Johnson M; Dickson RB; Lin CY
Am J Pathol; 2001 Apr; 158(4):1301-11. PubMed ID: 11290548
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease.
Kato M; Hashimoto T; Shimomura T; Kataoka H; Ohi H; Kitamura N
J Biochem; 2012 Feb; 151(2):179-87. PubMed ID: 22023801
[TBL] [Abstract][Full Text] [Related]
12. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor.
Kawaguchi T; Qin L; Shimomura T; Kondo J; Matsumoto K; Denda K; Kitamura N
J Biol Chem; 1997 Oct; 272(44):27558-64. PubMed ID: 9346890
[TBL] [Abstract][Full Text] [Related]
13. The Kunitz Domain I of Hepatocyte Growth Factor Activator Inhibitor-2 Inhibits Matriptase Activity and Invasive Ability of Human Prostate Cancer Cells.
Wu SR; Teng CH; Tu YT; Ko CJ; Cheng TS; Lan SW; Lin HY; Lin HH; Tu HF; Hsiao PW; Huang HP; Chen CH; Lee MS
Sci Rep; 2017 Nov; 7(1):15101. PubMed ID: 29118397
[TBL] [Abstract][Full Text] [Related]
14. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.
Kataoka H; Hamasuna R; Itoh H; Kitamura N; Koono M
Cancer Res; 2000 Nov; 60(21):6148-59. PubMed ID: 11085539
[TBL] [Abstract][Full Text] [Related]
15. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor.
Hashimoto T; Kato M; Shimomura T; Kitamura N
FEBS J; 2010 Dec; 277(23):4888-900. PubMed ID: 20977675
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma.
Yamauchi M; Kataoka H; Itoh H; Seguchi T; Hasui Y; Osada Y
J Urol; 2004 Feb; 171(2 Pt 1):890-6. PubMed ID: 14713848
[TBL] [Abstract][Full Text] [Related]
17. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
[TBL] [Abstract][Full Text] [Related]
18. Roles of functional and structural domains of hepatocyte growth factor activator inhibitor type 1 in the inhibition of matriptase.
Kojima K; Tsuzuki S; Fushiki T; Inouye K
J Biol Chem; 2008 Feb; 283(5):2478-87. PubMed ID: 18048349
[TBL] [Abstract][Full Text] [Related]
19. Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein.
Mitchell AC; Kannan D; Hunter SA; Parra Sperberg RA; Chang CH; Cochran JR
J Biol Chem; 2018 Apr; 293(14):4969-4980. PubMed ID: 29386351
[TBL] [Abstract][Full Text] [Related]
20. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]